ISA to Present Results of Randomized Phase II Study of ISA101b in Head and Neck Cancer at the ASCO Annual Meeting 2024

28 May 2024

Dr. Caroline Even (Institut Gustave Roussy, Paris), Principal Investigator, will present results from OpcemISA, a randomized, placebo controlled clinical trial in advanced head-and-neck cancer

Data from a state of the art double blind placebo controlled phase 2 trial in 199 patients with advanced HPV16 induced head and neck cancer give direction as to which patients are true candidates for ISA101b, to be confirmed in phase 3

Oegstgeest, 28 May 2024 – ISA today announces that Dr Caroline Even, oncologist at Institut Gustave Roussy, will present the results of the double blind OpcemISA clinical trial with 199 patients at the ASCO annual conference.

Read more »

ISA Pharmaceuticals to present at the ASCO Annual Meeting 2024

16 Apr 2024

An abstract detailing results from a randomized, placebo-controlled trial in advanced head and neck cancer, was accepted for oral presentation

Results provide key insights for the clinical application of cancer vaccines

Oegstgeest, 16 April 2024 – ISA today announced acceptance of its ISA101b study abstract as an oral presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual meeting. This abstract describes results of a randomized trial in advanced head and neck cancer with its lead therapeutic vaccine ISA101b.  These results provide key insights in the clinical application of cancer vaccines.

ISA101b is a cancer vaccine that targets human papillomavirus type

Read more »